The Neo Comprehensive - Myeloid Disorders assay analyzes 184 genes to detect DNA and RNA alterations through NGS for the purpose of diagnostic evaluation, prognosis, risk stratification, and therapy guidance of myeloid neoplasms. Test reports include a summary interpretation of all results together.
DNA sequencing SNVs/Indels (127 genes)
Copy Number Variants (CNV) (17 genes)
RNA sequencing Fusions (40 genes)
Test Customizations
FLT3 by PCR (via FLT3 Mutation Analysis) is available for concurrent testing, as Client-Bill only, in conjunction with the Neo Comprehensive Myeloid Disorders. It is reported separately from the Neo Comprehensive profile for the purpose of prompt therapy selection in patients with a new diagnosis of AML.
Neo Comprehensive - Myeloid Disorders
- Next Generation Sequencing (NGS)
- Epic Aura Integration
Specimen Requirements
Bone Marrow Aspirate: 2-3 mL in EDTA tube. Sodium heparin is acceptable.
Peripheral Blood: 3-5 mL in EDTA tube. Sodium heparin is acceptable.
H&E slide: Required, plus paraffin block.
Cut Slides: H&E slide (required) plus 10-14 unstained slides cut at 5+ microns.
Note on FFPE: Paraffin block is preferred. Do not use zinc fixatives. If submitting slides, please use positively-charged slides and 10% NBF fixative. Block and slide identifiers should be clearly written and match exactly with the specimen ID and specimen labeling as noted on the requisition.
Do not use: Mercury fixatives (B5). Highly acidic or prolonged decalcification processes will not yield sufficient nucleic acid to accurately perform molecular studies.
Note on fresh samples: NeoGenomics should receive within 7 days from collection for acceptable cell viability.
Note: Test is TNA-based. Please select Extract & Hold - TNA if specimen hold service is desired.
Storage and Transportation
Use cold pack for transport, making sure cold pack is not in direct contact with specimen. Ship same day as drawn whenever possible. NYS clients please provide date and time of collection. Please select Extract & Hold - TNA if specimen hold service is desired.
CPT Code(s)*
81455
Turnaround time
14 Days
Level of Service
- Global
Integrations
- Epic Aura
New York Approved: Yes
Clinical Significance
The Neo Comprehensive - Myeloid Disorders assay detects relevant aberrations for the purpose of diagnostic evaluation, prognosis, risk stratification, and therapy guidance. It covers a wide spectrum of myeloid neoplasms, including acute myeloid leukemia (AML); chronic myeloid leukemia (CML); chronic myelomonocytic leukemia (CMML); myelodysplastic neoplasms (MDS); myeloproliferative neoplasms (MPN), e.g., polycythemia vera (PV), primary myelofibrosis (PMF), and essential thrombocythemia (ET); myeloid neoplasms with eosinophilia and defining gene rearrangement; histiocytic neoplasms, such as Langerhans cell histiocytosis (LCH) or Erdheim-Chester Disease (ECD); mastocytosis; myeloid precursor lesions.
*The CPT codes provided with our test descriptions are based on AMA guidelines and are for informational purposes only. Correct CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payor being billed.
Biomarkers
DNA Sequencing
| SNVs + Indels | |||||
|---|---|---|---|---|---|
| ABL1 | ANKRD26 | APC | ARAF | ASXL1 | ATM |
| ATRX | BCOR | BCORL1 | BLM | BRAF | BRCA1 |
| BRCA2 | BRIP1 | CALR | CBL | CBLB | CBLC |
| CDKN2A | CEBPA | CHEK2 | CSF3R | CTC1 | CUX1 |
| CXCR4 | DDX41 | DKC1 | DNMT3A | ELANE | EPCAM |
| ERCC4 | ETNK1 | ETV6 | EZH2 | FANCA | FANCB |
| FANCC | FANCD2 | FANCE | FANCF | FANCG | FANCI |
| FANCL | FANCM | FBXW7 | FLT3 | G6PC3 | GATA1 |
| GATA2 | GFI1 | GNAS | GNB1 | HAX1 | HRAS |
| IDH1 | IDH2 | IKZF1 | IKZF3 | ITPKB | JAK2 |
| JAK3 | KDM6A | KIT | KMT2A | KRAS | MAP2K1 |
| MET | MLH1 | MPL | MSH2 | MSH6 | MYD88 |
| NF1 | NHP2 | NOP10 | NOTCH1 | NPM1 | NRAS |
| PALB2 | PDGFRA | PHF6 | PIGA | PML | PMS2 |
| PPM1D | PRPF8 | PTEN | PTPN11 | RAD21 | RAD51C |
| RB1 | RPL11 | RPL35A | RPL5 | RPS10 | RPS17 |
| RPS26 | RPS7 | RTEL1 | RUNX1 | SAMD9 | SAMD9L |
| SBDS | SETBP1 | SETD2 | SF3B1 | SH2B3 | SLX4 |
| SMC1A | SMC3 | SRP72 | SRSF2 | STAG2 | STAT3 |
| STAT5B | SUZ12 | TERC | TERT | TET2 | TINF2 |
| TP53 | U2AF1 | VHL | WAS | WRAP53 | WT1 |
| ZRSR2 | |||||
| CNVs | |||||
|---|---|---|---|---|---|
| ABL1 | ASXL1 | ATG2B | BRAF | CDKN1B | CDKN2A |
| DNMT1 | ETV6 | EZH2 | GSKIP | JAK2 | KMT2A |
| KRAS | MYC | RAD21 | TP53 | ||
RNA Sequencing
| Fusions | |||||
|---|---|---|---|---|---|
| ABL1 | AFDN | AFF1 | ALK | BCL11B | CBFB |
| CEP43 | CPSF6 | CREBBP | DEK | ELL | EP300 |
| ETV6 | FGFR1 | FLT3 | GLIS2 | JAK2 | KMT2A |
| MECOM | MLLT1 | MLLT3 | MRTFA | MYB | MYH11 |
| NTRK3 | NUP214 | NUP98 | PCM1 | PDGFRA | PDGFRB |
| PICALM | PML | PRDM16 | RARA | RBM15 | RPN1 |
| RUNX1 | RUNX1T1 | TCF3 | ZNF384 | ||
Fluorescence In Situ Hybridization (FISH)
| CNVs | |||||
|---|---|---|---|---|---|
| CBFB | |||||
Last Updated: March 31, 2026